huberman glp 1 GLP-1 Agonists Explained GLP-ONE + Receptor Activator |

Hannah Chandler, 35, from California, had tried and failed to lose weight for yearsbut then she discovered a medication that helped her shed 120 pounds in 18 months

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

They weren't taking GLP-1s to shed fatthey were using it for blood sugar control

Weight Management: Significant weight reduction offers additional benefits for obese patients